Akorn Recalls Halyard Chlorhexidine Oral Rinse Due to Crystallization
Akorn Inc is recalling Halyard 24-Hour Oral Care Kits containing chlorhexidine gluconate oral rinse due to crystallization and subpotent assay results.
What this means for you
Cosmetic or documentation issue. No expected health impact, but the manufacturer is correcting the affected products.
Our severity reasoning: The FDA classified this recall as Class III, which by definition is unlikely to cause adverse health consequences, fitting the 'Low' severity criteria for minor or theoretical risks.
Plain-English summary
Akorn Inc is recalling Halyard 24-Hour Oral Care Kits that contain 15 mL unit dose cups of 0.12% Chlorhexidine Gluconate Oral Rinse. The recall involves 101,952 unit dose cups distributed nationwide in the United States. The product was manufactured by Halyard Health Inc. and distributed by Halyard Sales, LLC.
The recall was initiated because of crystallization and subpotent out-of-specification assay results for chlorhexidine. This means the active ingredient in the affected units may not be at the intended strength. The FDA has classified this recall as Class III, indicating that use of or exposure to the violative product is not likely to cause adverse health consequences.
Consumers and healthcare facilities should check their inventory for the specific lot numbers and expiration dates listed in the recall notice. If the product matches the recalled lots, it should be removed from use and returned to the distributor or disposed of according to local regulations.
The recalled product
- Product
- Halyard 24-Hour Oral Care Kit q4, contains 2x15 mL Unit Dose Cups 0.12% Chlorhexidine Gluconate Oral Rinse. Manufactured by Halyard Health Inc., 5405 Windward Parkway, Alpharetta, GA 30004. Distributed by Halyard Sales, LLC Alpharetta, GA 30004. REF # 97014
- Manufacturer
- Akorn Inc
- Category
- Drug — Oral Rinse
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (19)
- Lots: 0202635072
- 0202635073
- EXP 06-2018
- 0202630205
- 0202630206
- EXP 07-2018
- 0202630203
- 0202630204
- 0202642217
- 0202642218
- 0202642219
- 0202647410
- 0202647411
- EXP 08-2018
- 0202647409
- 0202647412
- 0202653431
- 0202653432
- EXP 09-2018.
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 3 recalled by Akorn Inc under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 3 products in this recall →Related recalls
Same manufacturer · Akorn Inc
See all →- HighGuaifenesin Oral Solution Recalled Due to Incomplete Stability Studies
FDA (Drugs) · 2023-06-07
- HighAkorn Hydromorphone Hydrochloride Injection Recalled Due to CGMP Deviations
FDA (Drugs) · 2023-06-07
- HighFDA Recalls Calcitriol Injection Due to Manufacturing Practice Violations
FDA (Drugs) · 2023-06-07
- HighTobramycin Ophthalmic Solution Recalled Due to Incomplete Stability Studies
FDA (Drugs) · 2023-06-07
- HighMidazolam Injection Recalled Due to Manufacturing Compliance and Stability Study Issues
FDA (Drugs) · 2023-06-07
Same hazard · subpotent drug
See all →- HighAccord Healthcare Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- SevereAccord Healthcare Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- ModerateAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02